Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good

Karimi-Shah B, Chowdhury B . Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. N Engl J Med. 2015; 372(13):1189-91. DOI: 10.1056/NEJMp1500526. View

Maher T, van der Aar E, Van de Steen O, Allamassey L, Desrivot J, Dupont S . Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018; 6(8):627-635. DOI: 10.1016/S2213-2600(18)30181-4. View

Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C . Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2022; 386(23):2178-2187. DOI: 10.1056/NEJMoa2201737. View

Raghu G, Ghazipura M, Fleming T, Aronson K, Behr J, Brown K . Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the.... Am J Respir Crit Care Med. 2024; 209(6):647-669. DOI: 10.1164/rccm.202312-2213SO. View